Navigation Links
Leukemia pill shows promise against stomach cancer

Gleevec, which was just approved for treating leukemia, also shows promise against a type of stomach cancer . The Food and Drug Administration approved the use of a promising anti-leukemia drug for treatment of a relatively rare form of abdominal cancer. The drug, Gleevec, administered as a pill once a day, is effective in treating both forms of cancer because of its ability to target and kill cancer cells without attacking healthy cells and causing severe side effects. //

Approved last spring for a common type of adult leukemia, Gleevec can now be used to treat gastrointestinal stromal tumors, or GIST, which affect as many as 5,000 people in the US each year. Studies have shown it to be as effective in treating chronic cases of GIST as it has been in treating chronic myelogenous leukemia (CML).

Researchers reported 59 percent of patients with advanced-stage GIST went into remission and up to 75 percent showed some type of improvement with limited side effects. GIST accounts for about two percent of all abdominal cancers. If caught early, these tumors can usually be removed surgically, but growths often return. According to its manufacturer, Novartis Oncology, Gleevec also is being studied as a possible treatment for prostate cancer, small-cell lung cancer and a rare type of brain cancer.
'"/>




Page: 1

Related medicine news :

1. Cyclosporin A Treats Leukemia Complications
2. Aspirin Lowers Leukemia Risk
3. Hope for Chemo-Resistant Leukemia Patients
4. Genes Found To Help Leukemia Treatment
5. Looking Towards More Effective Leukemia Treatment
6. Diet Found To Offer Protection Against Leukemia
7. Exposure To Night Light may Increase The Risk Of Leukemia
8. Skin Allergies Found To Increase The Risk Of Leukemia
9. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
10. Night Light Found To Increase The Risk Of Leukemia
11. Treating Leukemia With Natural Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... , ... Nurses at Apple Rehab Watch Hill , a nursing and ... certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... for Medicare and Medicaid Services, to have a CPI machine that will provide better ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: